

Analytical Methods

Accepted Manuscript



This is an *Accepted Manuscript*, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this *Accepted Manuscript* with the edited and formatted *Advance Article* as soon as it is available.

You can find more information about *Accepted Manuscripts* in the [Information for Authors](#).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](#) and the [Ethical guidelines](#) still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this *Accepted Manuscript* or any consequences arising from the use of any information it contains.

Magnetic Immunoassay Based on Frequency Mixing Magnetic Detection and Magnetic Particles of Different Magnetic Properties

H.B. Hong,^a H.-J. Krause,^b I.H.Nam^c, C.J.Choi^d and S.W.Shin^a

Abstract

This paper presents a novel analytical system that employs two different types of magnetic particles (MP) with Frequency mixing magnetic detection (FMMD). Model experiment with MP and FMMD show that this method significantly reduces the steps involved in common immunobiological assays and enables repetition of the measurement without signal decay.

Main Manuscript

Magnetic particles (MP) have been widely used in many fields including biochemistry and medicine¹. The most common usage of MP in biochemistry is as a capturing agent for isolation and enrichment of the analyte(s) from complicated samples because of the easy magnetic manipulation^{2,3}. Other biomedical applications include their use as image tracers and contrast agents for Magnetic Resonance Imaging (MRI) and Magnetic Particle Imaging (MPI) and for drug delivery to specific targets⁴⁻⁸. Recently, the capability of MP as markers for labelling bio-materials such as DNA, proteins and even cells in a bioassay have been extensively researched and have led to many commercial applications^{1,9}. As markers in bioassays, MP is relatively stable because there is no signal decay, resulting in less fluctuation in signal intensity than those frequently observed in fluorescence- and enzyme-based assays. Among the various MP used, superparamagnetic nanoparticles are widely employed as markers because of their small disturbance to biochemical processes and because of their favourable magnetic properties¹⁰.

The use of magnetic particles for both manipulation of a sample and for labelling the analyte is beneficial because it simplifies the assay procedure. However, the following issues should be considered when using MP for both capturing and labelling the sample in one reaction simultaneously. The most important one is that the Probe Magnetic particles (PMP) generating the signal should not be separable by the usual magnets for magnetic separation. The PMP

1 should be attached to the capturing agent through a biochemical reaction with the analyte.
2 Only the capturing agent should be captured by the separation magnet. Finally, the magnetic
3 reader should detect a magnetic signal only from the PMP, with a high selectivity to PMP as
4 compared to other materials.

5 To fulfil these considerations, magnetic nanoparticles with 20 nm diameter comprising a
6 single magnetic domain were employed as the PMP. 500 nm diameter magnetic particles with
7 multiple magnetic domains which can be attracted by the external magnetic field were used as
8 the Capturing Magnetic Particles (CMP). The PMP could not be separated by a standard
9 separation magnet because their induced magnetic moment is too small due to their small size.
10 Thus, the PMP could only be separated when they were attached to the CMP. Only the large
11 CMP (with more than 50 nm diameter) exhibit a sufficiently large magnetic moment to be
12 attracted by the external magnet. For the measurement and quantification, the relatively new
13 Frequency Mixing Magnetic Detection (FMMD) technique was used. Previous research showed
14 the applicability of this method for the detection of PMP¹¹. Meyer *et al.* showed that C-reactive
15 protein, *Yersinia pestis* and *Francisella tularensis* labelled with PMP can be assessed by FMMD¹²⁻¹⁴.
16 Hong *et al.* used the method by combining enzyme-linked immunofiltration assay and FMMD,
17 resulting in the treatment of multiple samples and eliminating a few of the steps required for usual
18 ELISA assays¹⁵. By discriminating the specific nonlinear signatures of different types of magnetic
19 nanoparticles by observation of the frequency mixing components of higher order, it has been shown
20 that two different types of MP can be individually and simultaneously detected¹⁶.

21 To the best of our knowledge, this is the first bioassay employing two different magnetic beads
22 together for separation and labelling in one analytical procedure. Furthermore, the FMMD technique
23 can assess the amount of superparamagnetic material in the sample resulting in the direct
24 measurement of the sample without the need of transferring the sample. Repeated measurements of
25 the sample can easily be done. This is not possible for the usual immunobiological assays employing
26 enzymatic or fluorescent markers as labelling compounds because of rapid degeneration.

27 FMMD consists of a measurement head and an electronics for excitation and detection
28 frequency generation and for synchronous readout of the measured sum frequency
29 component^{11,17}. The magnetic measurement head comprises two excitation coils wound on the
30 same bobbin and the pick-up coil with two identical coils placed next to each other but wound
31 in opposite direction. The outer low frequency coil generates a 4 mT magnetic field at 61 Hz
32 which periodically drives the magnetic particles close to saturation. The other coil generates
33 an excitation field of 0.5 mT at 61 kHz. The magnetic moment sensitivity is given by the
34 Johnson noise of the detection coil. Based on the previous research¹¹, the noise equivalent
35 magnetic moment was calculated to $1.0 \times 10^{-13} \text{ Am}^2/\sqrt{\text{Hz}}$. In this method, two distinct frequencies
36 are applied to the superparamagnetic particles, resulting in the appearance of harmonic peaks and of

1 intermodulation products, due to the nonlinear magnetic characteristics of the MP. These peaks are
2 highly specific to the nonlinearity of the magnetic particles.

3 For the model experiments, two different types of magnetic particles were employed. PMP
4 with a hydrodynamic diameter of 20 nm (Nanomag®-D-sprio-biotin) were purchased from
5 Micromod Patrikletechnologie GmbH (Rostock, Germany). According to the manufacturers
6 description, the particles consist of about 55~85% (W/W) iron oxide (magnetite) in a matrix of
7 dextran (MW:40,000 Da), with varying diameter and surface modification. Electron
8 microscope data showed that 20 nm particles contain iron oxide crystals of 7.0~10 nm¹⁸. The
9 PMP were diluted 100-fold in Phosphate Buffered Saline (PBS, pH 7.5). Particles with a
10 hydrodynamic diameter of 500 nm from the same manufacturer, covered with biotin and also
11 diluted 100-fold in PBS, were employed as the CMP. The 500 nm particles have a core of
12 magnetite and a dextran shell. Based on the manufacturer's description, they can be separated
13 with a conventional permanent magnet. Avidin (Sigma Aldrich, MO) was serially diluted in
14 PBS containing 1.0% of bovine serum albumin (0.0, 3.0, 6.0, 12.0, 24.0, and 48.0 mg/mL),
15 and 900 µL of the serially diluted Avidin solution was mixed with 100 µL of the CMP. The
16 mixture was incubated for 15 min at room temperature. The mixture was then washed three
17 times and re-dissolved in 1.0 ml of PBS. Subsequently, 100 µL was transferred to another tube
18 and the amount of PMP was measured to determine the value of the unbound CMP. Then, 100
19 µL of the PMP solution was added and incubated for another 15 min. Finally, the mixture was
20 washed again with PBS three times and re-dissolved in 1.0 mL of PBS. From this, 100 µL was
21 measured with FMMD and the final value was obtained by subtracting the CMP measured
22 above. The whole experiment was triplicated. For statistical evaluation, a two-tailed Student t-
23 test was performed using Minitab 16 (Minitab Inc., PA) with a cut-off of $p < 0.05$.

24 Scheme 1 provides a schematic drawing of the analytical procedures used in this research. At the
25 first step, the CMP separated the Avidin analyte from the sample. Subsequently, the PMP were
26 attached to the CMP by the interaction between Avidin and its ligand, biotin. Thus, the amount of
27 bound PMP is proportional to the amount of analyte. Next, after magnetic separation, unbound PMP
28 are washed out. Only the PMP bound to CMP are quantified by the magnetic reader. In this work, the
29 discrimination between PMP and CMP is performed by recording the difference of the two signals
30 before and after magnetic separation. This analytical technique does not require different chemical
31 procedures and transfer of the sample between the procedures because all the materials for the
32 separation and labelling material are magnetic particles. This leads to a reduction of practical errors
33 during the assay. In addition, the effect of deterioration with time can be neglected because the
34 magnetic properties of the magnetic particles do not change with time. However, in case of other

1 bioassays employing enzymes or fluorescence, timing is a critical factor for the results because of the
2 dynamic and unstable properties of the substances used.

3 **[Position for Schematic 1]**

4 Figure 1 shows the results from the model experiment based on the principle suggested in
5 Scheme 1. Figure 1(a) shows the differences of nonlinear magnetization of the 20 nm and the
6 500 nm MP which are the basis of the experiments. The 20 nm magnetic beads cannot be
7 separated by the permanent magnet while the 500 nm magnetic beads can easily be retained by
8 the magnet. This means that 20 nm PMP can only be separated when they are bio-chemically
9 attached to the 500 nm CMP. Figure 1(b) shows that unspecifically bound PMP without
10 Avidin linkage to CMP do not have a significant effect on the intensity of the signal. Instead,
11 the measurement of bound PMP shows that addition of Avidin significantly increases the
12 signal intensity, meaning the signal intensity is related to the amount of Avidin analyte in the
13 solution.

14
15 **[Position for Figure 1]**

16
17 Figure 2 shows that the increase in Avidin concentration corresponds to the amount of the
18 PMP used in the experiment. By performing a linear fit to the data using Origin 8.5, a linear
19 dependence ranging from 9.39 to 37.9 ug/ml was found, with slope=2.17 and intercept=16.
20 The coefficient of determination (R^2) for the linear approximation was 0.96. The linear fit
21 yielded an offset of the signal intensity of 500 nm for zero PMP concentration. The results
22 from the measurement performed 3 hours after the first experiment showed that there was no
23 significant change. It is impossible to obtain such a result for enzyme- or fluorophore-based
24 immunoassays.

25
26 **[Position for Figure 2]**

27
28 Although magnetic beads have shown great utility in diagnostics and immunoassays both as
29 separation agents and as markers, little progress has been made on the commercialization and
30 standardization of the whole analytical system. We think that this is due to the lack of proper
31 analytical procedures after manipulation of the analyte by MP. Normally, the analyte is
32 labelled by a fluorophore or enzyme, instead of magnetic particles, after the magnetic
33 separation¹⁰. However, there are some drawbacks to using these conventional chemical and
34 biochemical markers because proper quantification cannot be performed due to light
35 scattering, aggregation, and distortion of signals from MP stacking. Magnetic particles have
36 not been used as markers because they would separate together. Furthermore, no suitable

1
2
3
4 1 magnetic reader has been available that could selectively retrieve information on the magnetic
5 2 signals from the PMP which are free in the solution. To date, magnetic field sensors such as
6 3 Giant magnetoresistance(GMR) and Superconducting Quantum Interference Device (SQUID)
7 4 have shown outstanding performance on the detection of PMP¹⁹⁻²¹. However, in order to use
8 5 GMR or spin valve sensors, the PMP must be immobilized on the surface, which requires the
9 6 transfer of the sample and additional chemical treatment. In addition, these sensors have a
10 7 small surface area, are laborious to manufacture, and have a very narrow detection range. For
11 8 example, the maximum number of PMPs of 50 nm size occupying an area of 100 $\mu\text{m} \times 100$
12 9 μm is about 4 million. SQUID suffer from similar problems, in addition to their cooling
13 10 requirements, a very expensive operation cost and the necessity for a skilled operator. ^{10, 22}.
14 11 FMMD is based on the frequency mixing at the non-linear magnetization curve of
15 12 superparamagnets. When the sample is excited by the two distinct frequencies, the response
16 13 signals of a linear combination ($m f_1 + n f_2$) is measured¹¹. The signal is representing the total
17 14 amount of particles in a certain volume, avoiding the immobilization of the biomolecules on
18 15 two- or three-dimensional substrates.

16 **Conclusions**

17 In summary, a new bio analytical method employing two different MP and a FMMD reader
18 has been established. The main idea of this study is to make use of the different magnetic
19 properties of MP and the selectivity of the FMMD technique. The large particles are used for
20 magnetic separation, the small particles for magnetic quantification by comparing the
21 magnetic signal before and after separation. Our results from the model experiments
22 employing biotin and Avidin showed that this method eliminates many of the typical
23 procedures required by conventional photometric methods. Additional benefits are that the
24 operator does not have to continue the labelling, quench the reaction, and perform
25 measurements in time, which are critical in other assays. Aggregation, stacking, and scattering
26 of light are not an issue in this study because FMMD techniques measure the sum of the
27 signals of all the MP in the sample. This method can increase the effectiveness and potential
28 capability of bioassays based on magnetic particles. With the scheme presented here, the field
29 of potential applications can be extended to most of the bioassays.

31 **Acknowledgements**

32 This work was financially supported by the Technology Innovation Program (Grant
33 No:10041066) funded by the Ministry of Science, ICT & Future Planning (MSIP, Korea).

35 **Notes and references**

^a IT Convergence Research Lab., Electronics and Telecommunications Research Institute (ETRI), Daejeon 307-700, Republic of Korea

^b Peter Grünberg Institute (PGI-8), Forschungszentrum Jülich, 52425 Jülich, Germany.

^c Geological Hazards Division, Korea Institute of Geoscience and Mineral Resources (KIGAM), Daejeon 305-350, Republic of Korea

^d Department of BIN Fusion Technology, Chonbuk National University, Jeonju 561-756, Republic of Korea

References

1. R. Ramanujan, in *Biomedical Materials*, ed. R. Narayan, Springer US, 2009, pp. 477-491.
2. S. Berensmeier, *Appl Microbiol Biotechnol*, 2006, **73**, 495-504.
3. M. Franzreb, M. Siemann-Herzberg, T. Hobley and O. T. Thomas, *Appl Microbiol Biotechnol*, 2006, **70**, 505-516.
4. S. R. Dave and X. Gao, *Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology*, 2009, **1**, 583-609.
5. L. Josephson, in *BioMEMS and Biomedical Nanotechnology*, eds. M. Ferrari, A. Lee and L. J. Lee, Springer US, 2006, pp. 227-237.
6. J. S. Weinstein, C. G. Varallyay, E. Dosa, S. Gahramanov, B. Hamilton, W. D. Rooney, L. L. Muldoon and E. A. Neuwelt, *J Cereb Blood Flow Metab*, 2009, **30**, 15-35.
7. B. Gleich and J. Weizenecker, *Nature*, 2005, **435**, 1214-1217.
8. P. W. Goodwill, E. U. Saritas, L. R. Croft, T. N. Kim, K. M. Krishnan, D. V. Schaffer and S. M. Conolly, *Adv Mater*, 2012, **24**, 3870-3877.
9. E. Choi, D. Loo, J. W. Dennis, C. A. O'Leary and M. M. Hill, *Electrophoresis*, 2011, **32**, 3564-3575.
10. V. Mani, B. V. Chikkaveeraiah and J. F. Rusling, *Expert opinion on medical diagnostics*, 2011, **5**, 381-391.
11. H.-J. Krause, N. Wolters, Y. Zhang, A. Offenhäusser, P. Miethe, M. H. F. Meyer, M. Hartmann and M. Keusgen, *Journal of Magnetism and Magnetic Materials*, 2007, **311**, 436-444.
12. M. H. Meyer, M. Hartmann, H. J. Krause, G. Blankenstein, B. Mueller-Chorus, J. Oster, P. Miethe and M. Keusgen, *Biosens Bioelectron*, 2007, **22**, 973-979.
13. M. H. Meyer, M. Stehr, S. Bhujju, H. J. Krause, M. Hartmann, P. Miethe, M. Singh and M. Keusgen, *Journal of microbiological methods*, 2007, **68**, 218-224.
14. M. H. F. Meyer, H.-J. Krause, M. Hartmann, P. Miethe, J. Oster and M. Keusgen, *Journal of Magnetism and Magnetic Materials*, 2007, **311**, 259-263.
15. H. B. Hong, H. J. Krause, K. B. Song, C. J. Choi, M. A. Chung, S. W. Son and A. Offenhäusser, *J Immunol Methods*, 2011, **365**, 95-100.
16. L. Lenglet, *Journal of Magnetism and Magnetic Materials*, 2009, **321**, 1639-1643.
17. H. Hong, H. J. Krause, S. Sohn, T. Baik, J. H. Park, S. Shin, C. Park and D. Song, *Anal Biochem*, 2014, **447**, 141-145.
18. S. N. Tabatabaei, J. Lapointe and S. Martel, *Intelligent Robots and Systems*, 2009. IROS 2009. IEEE/RSJ International Conference on, 2009.
19. D. Mitra, Ramli, H. Freddy and Khairurrijal, *GMR Biosensors for Clinical Diagnostics*, 2011.
20. L. Hao, D. Cox, P. See, J. Gallop and O. Kazakova, *Journal of Physics D: Applied Physics*, 2010, **43**, 474004.
21. Y. R. Chemla, H. L. Grossman, Y. Poon, R. McDermott, R. Stevens, M. D. Alper and J. Clarke, *Proceedings of the National Academy of Sciences of the United States of America*, 2000, **97**, 14268-14272.
22. C. S. Thaxton, H. D. Hill, D. G. Georganopoulou, S. I. Stoeva and C. A. Mirkin, *Analytical chemistry*, 2005, **77**, 8174-8178.





Figure 1. Measurement of (A) 500 nm diameter magnetic particles only, (B) mixture of 20 nm and 500 nm particles without Avidin (no biochemical linkage between the two magnetic particles), (C) mixture of 20 nm and 500 nm particles with Avidin. The measurement was performed after washing out the magnetic particles from the solution. For the calculation, the offset measured in (A) was subtracted from (B) and (C). The detailed experimental procedures are described in the text. All the experiments were triplicated.

1

2 FIGURE 2



3

4 Fig. 2. Measurement of signal intensity as a function of Avidin concentration. The square dots denote
5 the results from the measurement immediately after the reaction, the red circles were measured after 3
6 hours storage under usual atmosphere, showing the repeatability and stability of the method.

7

8

9

10

11

12


13

14

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1

2 SCHEME 1



3

4 Scheme 1 (A) Photograph of the two different magnetic particle samples showing the different
5 magnetization and basic principle of the experiment. (B) Schematic drawing of the analytical
6 procedure. 20 nm diameter Probe Magnetic Particles (PMP) with a single magnetic domain are bound
7 to Capturing Magnetic Particles (CMP, diameter 500 nm, with multiple magnetic domains) through a
8 reaction between analyte and capturing agent immobilized on the surface of the CMP. In this
9 experiment, the model compounds are Avidin and Biotin. The unbound PMP are washed out.
10 Quantification is performed by the measurement of PMP bound to the CMP using the Frequency
11 Mixing Magnetic Detection technique.

12